Rasagiline

Increased risk of adverse effects from almotriptan, including serotonin syndrome.

Almotriptan is contraindicated in patients who have taken an MAO inhibitor within the preceding 2 weeks.

Source: G&G 14e · p293, p302

Increased risk of adverse effects from rizatriptan, including serotonin syndrome.

Rizatriptan is contraindicated in patients who have taken an MAO inhibitor within the preceding 2 weeks.

Source: G&G 14e · p293, p302

Increased risk of adverse effects from sumatriptan, including serotonin syndrome.

Sumatriptan is contraindicated in patients who have taken an MAO inhibitor within the preceding 2 weeks.

Source: G&G 14e · p293, p302

Potentially life-threatening elevation of blood pressure (hypertensive crisis).

Avoid concurrent use of MAOIs and medications containing sympathomimetic compounds.

Source: G&G 14e

Marked increases in blood pressure (hypertensive crisis).

Patients on MAOIs must avoid foods containing high levels of tyramine, such as soy products, dried meats and sausages, dried fruits, home-brewed and tap beers, red wine, pickled or fermented foods, and aged cheeses.

Source: G&G 14e

Increased risk of adverse effects from zolmitriptan, including serotonin syndrome.

Zolmitriptan is contraindicated in patients who have taken an MAO inhibitor within the preceding 2 weeks.

Source: G&G 14e · p293, p302

Serotonin syndrome, characterized by hyperthermia, muscle rigidity, myoclonus, tremors, autonomic instability, confusion, irritability, and agitation, which can progress to coma and death.

SSRIs should not be started until at least 14 days following discontinuation of treatment with an irreversible MAOI. For all SSRIs except fluoxetine, at least 14 days should pass prior to beginning treatment with an MAOI following the end of SSRI treatment. For fluoxetine, at least 5 weeks should pass. For venlafaxine, a 7-day interval is considered safe between ending MAOI therapy and starting venlafaxine. For duloxetine, a 5-day waiting period is needed before beginning MAOI treatment after ending duloxetine.

Source: G&G 14e

Increased risk of adverse cardiovascular effects.

At least 2 weeks should elapse between the use of MAO inhibitors and administration of β2 agonists or other sympathomimetics.

Source: G&G 14e · p264

Severe, life-threatening orthostatic hypotension.

Not specified, but implies avoidance due to severe, life-threatening effect.

Source: G&G 14e · p1349

Delirium may occur.

Source: KDT 7e · p121

Increased risk of adverse cardiovascular effects.

At least 2 weeks should elapse between the use of MAO inhibitors and administration of β2 agonists or other sympathomimetics.

Source: G&G 14e · p264

Increased risk of adverse cardiovascular effects.

At least 2 weeks should elapse between the use of MAO inhibitors and administration of β2 agonists or other sympathomimetics.

Source: G&G 14e · p264